In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma in Specialist Land: No Proven Advantage Over Small Marketers

Executive Summary

Pfizer's move into the multiple sclerosis market last year, via its agreement to co-promote Serono's version of interferon beta-1a, posed a big challenge for Biogen, the leader in that market. Indeed, the situation is arguably the most visible experiment to date testing whether or not Big Pharmas--which lately have all begun moving into specialist markets--will have significant advantage over the small firms that have until now been the only ones to play there. Biogen's successful response to the challenge suggests that big companies can't dominate small markets just because they're big.

Related Content

Biogen Defends its Specialist Market
Biogen Defends its Specialist Market


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts